In 1991 Brian Evavold, at that time a postdoctoral fellow, and Paul Allen made a seminal report by introducing altered peptide ligands (APLs) into the field of Ag presentation and T cell activation ([1][1]). Since that time, numerous studies have attempted to explain the function of an APL. Other
No takes yet. Share an insight, caveat, or question.
Emil R. Unanue (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: